Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVTX-801 in PGM1-CDG
NCT05402332Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of D-galactose in phosphoglucomutase 1-related congenital disorder of glycosylation (PGM1-CDG) (2 arms). Primary endpoint: Proportion of participants with at least one PGM1-CDG related event at 18 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
D-galactose
03
Conditions
phosphoglucomutase 1-related congenital disorder of glycosylation (PGM1-CDG)
Beyond the preview
Go deeper on NCT05402332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05402332.